Houshang Sanadgol

Houshang Sanadgol

Auto-generated profile, based on publicly available information

Houshang Sanadgol

Department of Nephrology, Hasheminejad Kidney Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2025 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
NNNeda Najafi
Neda Najafi
HSHoushang Sanadgol
Houshang Sanadgol
HAHounaz Akbari
Hounaz Akbari
AKAsal Sadat Karimi
Asal Sadat Karimi
NSNegin Sanadgol
Negin Sanadgol
MVMohsen Vahedi
Mohsen Vahedi
Introduction: The COVID-19 pandemic has highlighted the vulnerability of patients with chronic kidney disease (CKD) to severe complications from the virus. Remdesivir, an antiviral drug initially developed for Ebola, has emerged as a treatment option for COVID-19, yet its safety and efficacy in patients with kidney disease remain under investigation. Objectives: This study aims to evaluate the complications associated with remdesivir in COVID-19 patients who have pre-existing kidney conditions. Patients and Methods: This retrospective cohort study involved 230 COVID-19 patients who were referred to Hasheminejad hospital in Tehran between October 2021 and July 2022, all of whom received a minimum of 100 mg of remdesivir. Participants were categorized based on their history of kidney disease into groups comprising those with CKD, end-stage renal disease (ESRD), and kidney transplant (KT) recipients as well as patients without a history of kidney disease including those with consistently normal kidney function. The study assessed demographic data and laboratory parameters related to liver function, specifically measuring alanine aminotransferase (ALT) and aspartate aminotransferase (AST), along with lactate dehydrogenase (LDH) levels, as well as inflammatory markers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), at both baseline and post-treatment intervals. Data were compared between groups using analytical tests. Results: Out of 230 included patients, 145 showed no kidney impairment, while 30 had CKD, 35 had undergone KT, and 20 were ESRD. The results indicated that there were no significant differences in liver enzyme levels (including AST and ALT), inflammatory markers (including CRP and ESR), and LDH, from pre- to post-administration of remdesivir between patients with kidney impairment and those without. Additionally, no differences were found among different kidney impairment groups such as CKD, KT, and ESRD. However, LDH and ESR levels were significantly higher in KT patients compared to those without kidney impairment, raising potential concerns for this population. Conclusion: The findings suggest that remdesivir-related complications concerning liver function, inflammatory markers, and LDH levels did not show significant differences between patients with or without kidney impairment, particular attention should be given to KT recipients due to observed significant increases in LDH and ESR, which may indicate a higher risk of adverse outcomes in this vulnerable population.

19 April 2026 in Journal of Nephropathology
Verified
Journal Article
Open access
PDF file
MNMohammadreza Nowroozi
Mohammadreza Nowroozi
AKAli Khalilzadeh
Ali Khalilzadeh
SBSeyed Amir Banikarim
Seyed Amir Banikarim
HSHoushang Sanadgol
Houshang Sanadgol
RARasoul Jafari Arismani
Rasoul Jafari Arismani
NNNaeem Nikpour
Naeem Nikpour
Introduction: Kidney cancer is a common tumor of the urinary system, and existing data on the relationship between sodium–glucose cotransporter 2 (SGLT2) inhibitors use and kidney cancer are inconsistent. Therefore, this study aimed to investigate the association between SGLT2 inhibitor use and the risk of developing kidney cancer. Materials and Methods: This study was designed as a systematic review and meta-analysis following the PRISMA guidelines. Accordingly, a comprehensive search was conducted in the Cochrane, Scopus, Web of Science, Embase, and PubMed databases, as well as the Google Scholar search engine, up to January 5, 2026. Data analysis was performed using STATA version 14. Results: The results showed that the association between the use of SGLT2 inhibitors (OR: 1.14, 95% CI: 0.86–1.52), dapagliflozin (OR: 1.67, 95% CI: 0.47–5.93), canagliflozin (OR: 1.59, 95% CI: 0.61–4.15), and empagliflozin (OR: 1.31, 95% CI: 0.52–3.27) with the risk of kidney cancer was not statistically significant. However, SGLT2 inhibitor use was associated with a reduced risk of renal cell carcinoma (RCC) (OR: 0.69, 95% CI: 0.63–0.76). In contrast, compared with dipeptidyl peptidase‑4 (DPP‑4) inhibitors, SGLT2 inhibitor use was linked to an increased risk of kidney cancer (OR: 1.64, 95% CI: 1.11–2.43). Conclusion: In conclusion, the use of SGLT2 inhibitors did not affect the incidence of kidney cancer, but it was associated with a 31% reduction in the risk of RCC. In contrast, compared with DPP‑4 inhibitors, SGLT2 inhibitor use increased the risk of kidney cancer by 64%. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420261293668) and Research Registry (UIN; reviewregistry2078) websites.

28 February 2026 in Journal of Renal Injury Prevention
Verified
Journal Article
Closed access
Sina Salem AhimSina Salem Ahim
Sina Salem Ahim
AMA. Mokhtariardekani
A. Mokhtariardekani
HSH. Sanadgol
H. Sanadgol
SHS. Hosseinian
S. Hosseinian
MSM. SalekShahabi
M. SalekShahabi
ZMZ. Hamidi Madani
Z. Hamidi Madani
Insulin resistance in polycystic ovary syndrome (PCOS) contributes to renal dysfunction through multiple interconnected mechanisms. In PCOS, insulin resistance leads to compensatory hyperinsulinemia, which exacerbates metabolic disturbances including hyperandrogenism and systemic inflammation. These factors collectively promote renal injury. Meanwhile, insulin resistance in PCOS promotes hypertension and endothelial dysfunction, which impair renal microcirculation. Hyperinsulinemia increases sodium retention and activates the renin-angiotensin-aldosterone system (RAAS), further elevating blood pressure and causing glomerular hyperfiltration and damage. Insulin resistance also contributes to dyslipidemia and oxidative stress, accelerating atherosclerosis and renal vascular injury. Moreover, insulin resistance worsens hyperuricemia by reducing renal uric acid excretion, which is a direct nephrotoxic factor. Persistent hyperuricemia leads to inflammation and fibrosis within the kidneys, potentially progressing to chronic kidney disease (CKD). In addition, systemic low-grade inflammation and oxidative stress driven by insulin resistance and PCOS-related hyperandrogenism also induce renal tissue injury through inflammatory cytokines and apoptotic pathways, contributing to impairment in renal function.